Barbara Pannone, PhD, is a Senior Director, US Access Strategy within Certara’s Evidence and Access Group. She has been a member of the team since 2006 and brings experience as a research scientist plus strong analysis and communications skills.
Barbara is responsible for leading our team of analysts in the execution of key projects. Barbara has managed projects in a variety of therapeutic areas including rare diseases, oncology, cardiovascular disease, and acute care. She has helped develop strategic conclusions and recommendations for various US and global market access assessments, pricing and reimbursement and due diligence assessments. Barbara has special interests in rare diseases and developing market access strategies for products in early stages of development, and has expertise in moderating discussions with thought leaders and payers both in the US and EU.
Prior to joining Certara Evidence & Access, Barbara worked as a Postdoctoral Associate at Yale University where she studied RNA binding proteins and their role in protein/RNA complex assembly.
Barbara received a PhD in Cell and Molecular Biology from Yale University and has been the lead author on several scientific papers on RNA binding proteins and co-author on a number of others.
In addition to a PhD from Yale University, Barbara earned a B.S. in Biology from Brown University. She also interned with Bayer R&D in the Alzheimer’s Research Group.